Will See Growth From Newly Launched Medicines in 2019, Says Roche’s CEO

The video discusses the company's successful 2018 results driven by new medicines and anticipates continued growth in 2019. The focus is on innovation and defending intellectual property against biosimilar competition. The impact of US healthcare policies on pricing is explored, emphasizing the importance of innovation. The company's M&A strategy remains opportunistic, with interest in neuroscience and oncology. Finally, the relationship with Novartis and its stake in the company is addressed.

What was the primary driver of the company's growth in 2018?

• Expansion into new markets

• Increased marketing efforts

• Newly launched medicines

• Cost-cutting measures

How does the company plan to handle biosimilar competition in the US?

• By forming alliances

• By focusing on innovation

• Through legal means

• By reducing prices

What is the company's approach to mergers and acquisitions?

• Pursuing mega mergers

• Focusing on small, strategic deals

• Avoiding any acquisitions

• Merging with competitors

Which area is the company particularly excited about for future growth?

• Gastroenterology

• Dermatology

• Neuroscience

• Cardiology

What is the company's stance on Novartis's stake in them?

• They want to buy it back

• They are indifferent

• They are happy with it

• They want Novartis to sell it